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I. INTRODUCTION

Significant resources were marshaled for the Human Genome Project in
the expectation that medical research breakthroughs would be forthcoming.
The initial results of medical re-sequencing efforts have been published, yet
the goal of translating this knowledge into clinically useful genomic tests
remains elusive. Advances in disease diagnosis and treatment require
continuing financial support, as well as the participation of patients and
normal individuals in genomic analysis studies. As the cost-benefit ratio of
genomic efforts continues to escalate, re-evaluation of the bottlenecks to
The barriers to successful
translational research may be helpful.
translational genomics research efforts include the intrinsic complexity of
human genetics, as well as extrinsic factors such as high expectations and
statutory restrictions, including the Health Insurance Portability and
Accountability Act (HIPAA).' Additionally, the Bayh-Dole Act, intended
to facilitate translational research by promoting interaction between the2
public and private sectors, may have had unintended consequences.
Rewarding basic science researchers with strong intellectual property rights
may not facilitate the development of clinical applications. The debate
regarding gene patent rights and a theoretical biotechnology anti-commons
is revisited in light of recent research results suggesting that genetic
diversity among individuals is greater than previously anticipated. In
addition, judicial decisions limiting the rights of patient-participants in the
translational research enterprise are discussed in light of increasing
. Michael Tomasson, M.D.
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demands for patient participation. The ideal route to returning the
investment in genomics research and providing benefits to society remains
unclear.
However, mutation profiling has suggested a power-law
distribution, or long tail distribution, prompting consideration of open
source strategies. Increasing patient participation and fulfilling the promise
of genomic research may require creative approaches to intellectual
property.
II. THE ETHICAL IMPERATIVE TO TRANSLATE SCIENTIFIC
PROGRESS INTO USEFUL ART

The human genome project, whose completion was hailed on April 15,
2003 by a ceremony at the White House, is considered a starting point for
large-scale medical "re-sequencing" efforts. For example, a study was
completed at the Washington University School of Medicine to discover
tyrosine kinase mutations in acute myeloid leukemia (AML). 3 A three-year,
$100 million Cancer Genome Atlas project, and a 1,000 Genomes project
have begun to provide voluminous data on mutated genes and the potential
roles that these mutated genes play in the development of cancer.4 Our goal
in the AML study was to perform "translational research," i.e. to translate
such basic research findings into useful improvements to clinical care.
Both our funding agencies 5 (e.g. the National Institutes of Health) and
patient advocacy groups 6 are very clear that they provide support for basic
research with the expectation that these insights will have measurable
impact on disease treatments. 7 The high cost of large-scale projects relative
to previous biomedical endeavors is justified by the potential payoffs for
medical advances.
In addition to biomedical researchers, integral participants in the human
genetics research projects include, of course, the patient-participants, as
well as private funding donors who raise money through fundraising events
(such as races and walks) with the explicit goal of translating these moneys
into cures for the diseases that often have affected participants' families.8
3. Michael H. Tomasson et al., Somatic Mutations and Germline Sequence Variants in
the Expressed Tyrosine Kinase Genes of Patients with De Novo Acute Myeloid Leukemia,
111 BLOOD 4797, 4798 (2008).
4. See, e.g., The Cancer Genome Atlas Research Network, Comprehensive Genomic
CharacterizationDefines Human Glioblastoma Genes and Core Pathways, 455 NATURE
1061, 1061 (2008).
5. E.g., National Institutes of Health.
6. E.g., Multiple Myeloma Research Foundation.
7. National Institutes of Health, About Us, http://clinicalresearch.nih.gov/about.html
(last visited February 9, 2009); see Jerome Groopman, Buying a Cure, NEW YORKER, Jan.
28, 2008, at 38.
8. Genetic Disease Foundation, Fundraising, http://www.geneticdiseasefoundation.org/
fundraising.html (last visited February 9, 2009).
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Also, government agencies, including the National Cancer Institute, have
begun to view money spent on genetics and cancer research as an
investment. 9 This implies that the United States government, its citizens,
and patients all view their participation, financial and otherwise, in this
research endeavor at some level as a quid pro quo-with the expectation
that returns on these investments will be forthcoming. Therefore, outside of
the law, there is an ethical responsibility to try to meet these expectations.
Accordingly, the issue becomes how to address the problems of searching
for value and patient participation in an ethical fashion.
For decades, genetic researchers have made remarkable progress in our
understanding of biology one gene at a time. In the age of genetics, the
vastness of the human genome ensured that considerable mystery and
uncertainty regarding "other factors" inevitably accompanied consideration
of the role between genes and disease (or phenotype). However, recent
breakthroughs in sequencing technology are rapidly changing the landscape
of our understanding by eliminating unexplored areas of the genome as
sources of uncertainty. Elucidating the vastness of the human genome by
complete sequencing is no longer the rate-limiting step in our attempts to
understand human biology.'°
A. Terminology Can Be Misleading
Evolving and imprecise terminology is a significant problem in the field
One issue
of genetics, where advancement is occurring so rapidly."
includes the differences between the traditional field of "genetics" and the
newer field of "genomics." The power and utility of traditional genetic
approaches-including forward genetic screens using model organisms to
identify genes responsible for particular phenotypes and linkage
disequilibrium studies to identify genes associated with familial diseasesare well-established.1 2 In contrast to genetics, which tends to examine one
gene at a time, genomics is a newer discipline that examines the regulation
and function of many genes at once.' 3 Therefore, this article posits that the
legal and cultural frameworks developed during the genetic era must be

9.

See generally NAT'L CANCER

INST., CONNECTING THE NATION'S CANCER COMMUNITY:

AN ANNUAL PLAN AND BUDGET PROPOSAL FISCAL YEAR 2010 (2009), available at

http://plan.cancer.gov/pdf/nci_201 _plan.pdf.
10. David R. Bentley et al., Accurate Whole Human Genome Sequencing Using
Reversible Terminator Chemistry, 456 NATURE 53, 58 (2008).
11. See Mark B. Gerstein et al., What Is a Gene, Post-ENCODE?History and Updated
Definition, 17 GENOME REs. 669, 671 (2007).
12. See Jonathan C. Cohen, Genetic Approaches to Coronary Heart Disease, 48 J. AM.
COLL. CARDIOLOGY Al0, A10 (2006).
13.

E.g., ENvTL. PROT. AGENCY,

SCIENCE POLICY COUNCIL,

INTERIM POLICY

ON

GENOMICS 2 (2004), availableat http://epa.gov/osa/spc/pdfs/genomics.pdf.
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refocused for the era of genomics.
Older terminology that has failed to keep up with the rapid evolution
from genetics to genomics has resulted in a pervasive sort of synecdoche,
where a part of the whole is used to refer to the whole.1 4 We can start with
the term "gene" itself. The concept of a basic unit of heredity was imagined
by Gregor Mendel in the 1860s, and the term "gene" was coined in 1905 by
Wilhelm Johannsen, who also studied the inherited characteristics of
plants. 1 5 With extensive study of genes and their linear sequences (of
adenine, A; guanine, G; cytosine, C; and thymine, T) over the past 50 years,
George Beadle's and Edward Tatum's "one gene, one enzyme" hypothesis
has collapsed under the weight of complexity. 16 Alternative splicing
(editing of the RNA that transcribed from DNA), alternative translational
starts (how the RNA is made into protein), and non-coding RNAs (the
realization that "junk DNA" is not so junky after all), have all made the
term "gene" a useful shorthand, but a beast to define rigorously.' 7 When we
refer to "the" gene for a certain disease or protein (e.g. BRCA1), we are
using a shorthand for "genome" that remains useful for scientific
communication, but may cause issues when applied to legal analyses. 18
If a gene can be thought of as a paragraph in a book without punctuation,
spacing, or indentation, then "the genome" of an organism can be viewed as
a library filled with completed works of genetic information contained
within the nucleus of each cell. In an age where digital reproductions are
expected to flawlessly reproduce tests at our command, it is important to
remember that, in truth, genetic information is analogue. Much like the
laborious, line-by-line hand copying of manuscripts by medieval monks, the
copying of genetic material from cell to cell and generation to generation by
the process of cell division is not perfectly accurate.' 9 In reality, therefore,

14.
15.
16.

See Gerstein et al., supra note 11, at 671.
Id. at 669.

PAUL BERG & MAXINE SINGER, GEORGE BEADLE, AN UNCOMMON FARMER: THE
EMERGENCE OF GENETICS IN THE 20TH CENTURY (2003); Rowland H. Davis, Beadle's

Progeny: Innocence Rewarded, Innocence Lost, 32 J. BIOSCIENCES 197, 202 (2007)
(discussing the increased complexity in the study of genes in the aftermath of Beadle's
hypothesis). The concept that genes, a vague unit of heredity, were somehow involved in
making enzymes, the regulators of cellular processes, had been around since the turn of the
century, but Beadle and Tatum set out to obtain experimental proof of the relationship.
Working with bread mold as a manipulable system, they induced mutations in genes with
radiation, and demonstrated that one mutation corresponded to the inactivation of one
enzyme. Berg & Singer, supra, at 136-61. This was a milestone in the history of biology,
but we know now that the relationship between genes and their products in much more
complex. See Davis, supra.
17. See Gerstein et al., supra note 11, at 676-79.
18. See, e.g., Paula W. Yoon, Risk Predictionfor Common Diseases, 66 LA. L. REv. 33,
36 (2005).
19. E.g., Genome News Network, Genome Variations, http://www.genomenewsnetwork
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no two genomes are completely identical. Despite the common use of the
phrase, "the human genome," in reality there is no such singular beast. The
use of the term has been extremely helpful to conceptualize and emphasize
the significance of genomic achievements, 20 and also to mobilize significant
funding for genomic research. To rally the public and political interests, the
sequencing community needed to communicate the potential utility and
grand scale of sequencing efforts.21 It is unlikely the necessary political and
financial support could be summoned for this massive technical effort if it
were more accurately titled, "Project to Sequence Nearly All of a Human's
Genome." The genomes of identical twins and other clonal organisms are
nearly identical, but it is an inherent and critical fact of biology that
individual organisms within a species living outside the laboratory have
unique genomes.22
Progress in our understanding of human genetics has revealed that
23
commonly used terminology is vague and occasionally misleading. In an
era where researchers are sequencing genes and genomes, and are
attempting to understand the meaning of single nucleotide differences and
how they relate to human disease, the scientific community has often used
the term "mutation" to mean a "nucleotide change that leads to disease. 24
However, this term may be fraught with difficulty as more single nucleotide
changes are identified because of the negative connotation of the term and
the possibility that some DNA changes are only weakly associated with
disease, if at all. When there is a difference at the nucleotide level, this
difference can be termed a single nucleotide polymorphism (SNP), or a
particular nucleotide letter that is not the same between individuals. The
SNP is generally considered to be benign or neutral, whereas mutation is
implies a causative association with disease.2 6 However, the boundaries
between these classes of nucleotide changes may be unclear. Somatic
changes refer to DNA changes that occur after birth-in a cancer cell, for
example-and a germline change is a congenitally-acquired change in the
nucleotide that occurs during meiosis, or before birth.27 Even the relatively
neutral term SNP has, in the past, implied a certain frequency of occurrence

.org/resources/whats a_genome/Chp4_l.shtml (last visited Apr. 24, 2009).
20. See generally Eric S. Lander et al., Initial Sequencing and Analysis of the Human
Genome, 409 NATURE 860 (2001).
21. See Catherine M. Valerio Barrad, Genetic Information and Property Theory, 87 Nw.
U. L. REv. 1037, 1041 (1993)
22. Id. at 1050 n.2.
23. See, e.g., Yoon, supra note 18, at 36.
24. Genome News Network, supra note 19.
25. Id.
26. Id.
27. E.g., EDWIN H. McCoNKEY, How THE GENOME WoRKs 19 (2004).
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that may not be true for rare polymorphisms.28 Additionally, the difference
between a rare polymorphism and a germline mutation is unclear.29
Therefore, it may be wise to use the completely value-neutral base change
or nucleotide change from a reference standard when discussing DNA
heterogeneity.
A subtle but profound shift in our understanding of human genetics has
recently begun to expose inaccuracies and inadequacies in the terminology
commonly used to discuss human genetics. 30 For example, the article "the"
is frequently misleading when used in biomedical research, as in "the
human genome," or "the breast cancer susceptibility gene," when it actually
refers to a single example of a class of nucleotide sequences united by
similar functions. Accordingly, intellectual property law that is based on
such inaccurate or misleading language may not sufficiently facilitate the
development of useful genomic technologies.
B. Genomic Research Has FailedThus Farto Yield
Useful Genomic Tests
While it is well-known through decades of genetic research that
mutations in single genes cause many congenital diseases, such as sickle
cell anemia and cystic fibrosis, 3' the influence of multiple genes is required
to cause more common diseases, such as cancer and hypertension. Thus,
the relatively new field of genomics research emerged to develop
understanding of the complex relationship between the changes to multiple
genes and the potential effects on common diseases.32 The vast potential of
genomics research became evident with the invention of oligonucleotide
microarrays.33 However, using genomics research, microarrays, and now
28. See generally Anthony J. Brooks, The Essence of SNPs, 234 GENE 177, 177 (1999).
High throughput re-sequencing studies (for example, Tomasson et al., supra note 3) are
finding increasing numbers of "germline sequence variants" that occur at a frequency of 1%
or less. Id.
29. Id. Germline changes that are clearly pathogenic, for example changes in the gene
encoding the ion transporter causing cystic fibrosis, are usually referred to as "mutations"
rather than SNPs, but where the change occurred during meiotic recombination or in utero, it
cannot be ascertained definitively without genotyping both parents, which has not been done
in large re-sequencing studies so far.
30. Yoon, supra note 18, at 36.
31. Lander et al., supra note 20, at 912; Rachel E. Ellsworth et al., Comparative
Genomic Sequence Analysis of the Human and Mouse Cystic Fibrosis Transmembrane
Conductance Regulator Genes, 97 PROC. NAT'L ACAD. SCI. U.S. 1172, 1172 (2000).
Mutations in the beta globin and CTFR genes cause sickle cell anemia and cystic fibrosis,
respectively. Id.
32. Jade Boyd, Simulated Populations Used to Probe Gene Mapping, RICE U., Mar. 29,
2007, http://www.media.rice.edu/media/NewsBot.asp?MODE=VIEW&ID=9430.
33. Mark Schena et al., Quantitative Monitoring of Gene Expression Patterns with a
Complementary DNA Microarray,270 Sci. 467, 467-70 (1995). By using robotic methods
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genome-wide sequencing efforts to understand complex traits, such as
cancer, has been a daunting task.34 Large sums of money have been spent,
and are being spent, to determine and catalogue genetic sequences of
diverse species, including humans; similarly, much money has been put into
microarray and other genetic analyses of patient samples. 35 The problem is
that researchers in the biomedical arena have yet to clearly demonstrate
value and utility in medical care of the majority of DNA-based tests for
common, polygenic diseases. 36 Are genome-sequencing technologies in the
biotechnology era akin to that of the gold rush in the western United States,
when the promise of gold stimulated economic activity and created
opportunities for merchants who catered to the needs of the miners and
families, even though the promise of gold never materialized for most
prospectors? If so, the first issue becomes how to utilize these genomic
tests and high throughput technologies, which we have imbued with such
high hopes. Then, we must determine how to extract clinical utility from
these technologies.37
Previous successful genetic analyses for single genes, such as sequencing
of the beta globin gene in patients with sickle cell anemia, have had such
adapted from the computer industry, the technology for measuring gene expression (i.e. how
much RNA a gene is producing as an index of its activation/importance) was turned on its
head. Instead of traditional methods that measured gene expression one gene at a time,
microarrays assay thousands of genes simultaneously. For the first time, experiments could
examine the entire genome (i.e. genomics) instead of having to focus hypotheses on one
gene at a time (i.e. genetics). Sequencing DNA has undergone a similar revolution whereby
15 years ago one gene would be sequenced at a time, and now entire genomes are being
decoded. Although the power of genomic approaches for basic science investigations has
been tremendous, the clinical use of genomic technology is not yet common practice. See
Andreas Rosenwald & Louis M. Staudt, Clinical Translationof Gene Expression Profiling
in Lymphomas and Leukemias, 29 SEMINARS ONCOLOGY 258, 2580-63 (2002).
34. Id. at 145.
35. Cf
Deirdre Meldrum, Automation for Genomics, Part Two: Sequencers,
Microarrays, and Future Trends, 10 GENOME RES. 1288, 1298 (2000) (describing
technological innovations resulting in breakthroughs in genomic research, but noting that
investments are necessary in order to spur more dramatic discoveries in the future).
36. See infra Part IV.A and accompanying notes.
37. John Hardy & Andrew Singleton, Genomewide Association Studies and Human
Disease, 360 NEw ENG. J. MED. 1759 (2009). The authors review the current state of the art
of genetic risk prediction science, and maintain great optimism that, "the jigsaw puzzle of
understanding the causes of disease lies before us: we now have the edges and corners in
place." Id. at 1767. However, the authors acknowledge that, "we will probably need
reference sequences from tens or hundreds of thousands of subjects," to achieve these goals.
Id at 1765. In the same issue of the New England Journal of Medicine, another author
points out that the study of common variants has been disappointing and will likely continue
to be so, and that attention should turn to the study rare variants, i.e. search the genomes of
many patients for particularly informative DNA variants. David B. Goldstein, Common
Genetic Variation and Human Traits, 360 NEw ENG. J. MED. 1696, 1698 (2009); see also
Joel N. Hirschhorn, Genomewide Association Studies-IlluminatingBiologic Pathways, 360
NEw ENG. J. MED. 1699, 1699-1701 (2009).
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strong predictive power that even studies using a small number of patientparticipants could determine whether the tests were valid.38 If genetic
markers will have only small effects, however, combinations of these
markers may need to be analyzed in parallel, and much larger numbers of
patients will be needed to provide the statistical power necessary to
demonstrate the validity of these tests. 39 Recent genome-wide association
studies have shown relative risks that are very mild (i.e. "Patient A" has a
1.2 fold increased risk of developing breast cancer). Though such findings
are statisticallyvalid, they provide little or no clinically useful information.
For example, while it is clear that the patient has an increased risk of
developing breast cancer, the findings cannot predict whether or not a
particular patient will develop cancer, and it is unclear what (if anything)
the patient can do to address such a miniscule increase in risk.4 °
From the perspective of a physician-scientist in the genomics field, one
clear challenge is that in order to identify meaningful implications in these
tests, there must be enough patient participation in clinical trials to identify
subtle effects. In the setting of tertiary academic research centers, where
one of the primary missions is to put patients in clinical trials, it is
understood that most patients treated for cancer in the United States are
treated in the community, and are not enrolled in clinical trials. 41 Therefore,
the corollary challenge is to increase patient participation in clinical trials in
order to test and understand the validity of novel DNA tests.
The rarity of discovered mutations, or the perception of overlap with
other intellectual property, may discourage the pursuit of exclusive patent
rights on novel genetic findings. Our group recently conducted a genomic
analysis of acute myeloid leukemia (AML) patient DNA in the proper,
pharmaceutically-driven way, as a search for new drug targets for this
disease. 42 We were the first group to describe such cancer-associated
mutations in a gene called JAKI. Our group did not pursue a patent
application on this potentially useful finding, because the low cost and
widespread use of available AML tests made the development of complex

38. E.g., Antonio A. Reyes et al., Ligase Chain Reaction Assay for Human Mutations:
The Sickle Cell by LCR Assay, 43 CLN. CHEMISTRY 40, 40 (1997). In a study of twenty-four
subjects, researchers, using an assay to detect beta-globin sickle cell mutation, concluded
that the assay unequivocally discriminated among normal, carrier, and sickle cell genotypes.
Id.
39. See David C. Whitcomb, Polygenetic Traits in Pancreatic Disorders, 35
ENDOCRINOLOGY & METABOLISM CLINICS N. AM. 255, 256-68 (2006).
40. See generally Hirschhorn, supra note 37, at 1699-1701.
41. US Oncology, Advancing Cancer Care, June 1, 2007, ALLIANCE HEMATOLOGY &
ONCOLOGY, http://www.yourcanceralliance.com/newsdetails.cfm?newslD=6.
42. See Zhifu Xiang et al., Identification of Somatic JAK1 Mutations in Patients with
Acute Myeloid Leukemia, 111 BLOOD 4809,4809-10 (2008).
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clinical diagnostic tests less attractive than pursuing basic cell biology.4 3
The development of pharmaceuticals that do not affect large numbers of
patients might not proceed despite promising results in the laboratory. 44
JAKI mutations have since been found to be more common in a different
yet still rare form of leukemia,45 and it remains to be seen what impact, if
any, these findings will have on patient care.
C. CulturalFears and Misperceptions
A strong cultural rejection of genetic determinism may represent a
barrier to the adoption of genomic tests.46 The value of genomic testing
may reside most clearly in establishing risks for certain diseases and other
genetic proclivities.47 Such testing, therefore, would be an assay of
germline changes present from birth.48 The Hollywood movie Gattaca is an
allegorical representation of this cultural rejection. Gattaca envisions a
futuristic society, in which parents select fertilized eggs to carry to term on
the basis of the eggs' genetic profiles. 49 Then, society directs one's future
employment-whether one becomes a janitor or a rocket scientist-based
on the results of these genetic profiles. 50 The dystopia portrayed in this film
does not rely on any outlandish scientific progress.5' Many of the
technologies could conceivably exist, although the speed at which the
genetic tests are performed in the movie is unrealistic.52 The idea of a
world in which privacy is routinely violated through detection and analysis
of one's DNA based on the cells one leaves behind, and in which
discrimination in the work place becomes commonplace, is viscerally
43. At the U.S. Patent and Trademark Office (USPTO) patent database, searching
"JAKI" in the claims of issued patents yielded seven patents, and more patents affect the
close family member JAK2. USPTO, Patent Full-Text and Full-Page Image Databases,
http://patft.uspto.gov (last visited May 17, 2009).
44. See discussion infra Part II.C; Carol Rados, Orphan Products: Hopefor Peoplewith
Rare Diseases, FDA CONSUMER MAG., Nov.-Dec. 2003, at 10, available at http://
www.fda.gov/fdac/features/2003/603 orphan.html.
45. See Elisabetta Flex et al., Somatically Acquired JAKI Mutations in Adult Acute
Lymphoblastic Leukemia, J. EXPERIMENTAL MED. 751, 751-58 (2008).
46. See generally David A. Kirby, The New Eugenics in Cinema: Genetic Determinism
and Gene Therapy in GATTACA, 27 Sci. FICTION STUD. 193 (July 2000), available at
http://www.depauw.edu/sfs/essays/gattaca.htm.
47. See Torsten 0. Nielsen, Human Germline Therapy, 3 MCGILL J. MED. 126, 126
(1997).
48. See id.
49. Gattaca (Columbia Pictures 1997).
50. ld.
51. See Evan Brown, GattacaNow!, NEW HAVEN ADVOCATE, Nov. 1, 2007, availableat
http://www.newhavenadvocate.com/article.cfin?aid=3943.
52. See Genetics Home Reference, What is the Cost of Genetic Testing, and How Long
Does it Take to Get the Results?, http://ghr.nlm.nih.gov/handbook/testing/costresults (last
visited Feb. 9, 2009).
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abhorrent to most Americans. 53 When genes for a certain trait or disease
are described, the probabilistic nature of the outcomes is not routinely
explained or well understood.5 4 Thus, even if the tests are used in a positive
way, for example, to predict disease or to direct a therapy, there may be
unrealistic expectations of the power these tests have in predicting
biological future. Therefore, better science education, specifically in the
area of biology, will teach society to reject the false dichotomy of nature
versus nurture and to appreciate the power of genetic tests while
understanding that genetic determinism is a rare phenomenon.5 5 At the end
of Gattaca, the hero demonstrated his ability to overcome the prejudices of
society, which had catalogued him purely on the basis of his DNA
sequence. Certainly, the message-that while our DNA sequence may
change the probability of certain disease risks and outcomes, the
environment and our own choices
have a profound effect on the ultimate
6
outcome of our lives-is valid.
In addition to the public's poor understanding of the basics of genetics
and biology, there is also a widespread cultural bias toward medicine as a
pharmaceutical science.57 The tremendous success of pharmaceutical
medicine in providing antibiotics and successful chemotherapies has given
rise to a biomedical research enterprise that is completely dominated by the
pharmaceutical industry model. 58 This pharmaceutical model, simply
stated, is that there is a drug for everything.59 While there has been a recent
53. See, e.g., NewsHour with Jim Lehrer (PBS television broadcast June 7, 2001)
(transcript available at http://www.pbs.org/newshour/bb/health/jan-june01/genetest_0607.html) (last visited Feb. 9, 2009).
54. See
The National
Health
Museum,
Understanding
Gene
Testing,
http://www.accessexcellence.org/AE/AEPC/NIH/gene19.php (last visited Feb. 9, 2009).
55. See, e.g., David B. Resnik & Daniel B. Vorhaus, Genetic Modification and Genetic
Determinism, 1 PHIL. ETHICS & HUM. MED. 1, 9 (2006), available at
http://www.pubmedcentral.nih.gov/picrender.fcgi?artid= 1524970&blobtype=pdf.
56. See id
57. See generally lain M. Cockburn, The Changing Structure of the Pharmaceutical
Industry, 23 HEALTH AFF. 10, 10-22 (2004), available at http://content.healthaffairs.org/
cgi/reprint/23/1/10.
58. See id.
59. See MARCIA ANGELL, THE TRUTH ABOUT THE DRUG COMPANIES 250 (2004). Many
are critical of the practices of the pharmaceutical industry. Recent attention has focused on
the rebellion of medical students against the influence of the pharmaceutical industry on
their educations. Duff Wilson, Patching a Wound, N.Y. TIMES, Mar. 3, 2009, at B1;
Gardiner Harris & Benedict Carey, ResearchersFail to Reveal Full Drug Pay, N.Y. TIMES,
June 8, 2008, at Al. My contention is that there exists a profound and underappreciated
level of pharmaceutical industry influence on the biomedical research enterprise beyond the
explicit financial ties that have recently made news. Specifically, the paradigm that, for
example, cancer research should focus on "novel targets" for drug development ignores the
potentially greater impact that cancer prevention could have. See generally DEVRA DAVIS,
THE SECRET HISTORY OF THE WAR ON CANCER (2007). Dr. Davis' argument, although heavy
with conspiracy, theorizes that the focus of the biomedical enterprise has been directed by
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focus on the efforts of the pharmaceutical industry to influence the
prescribing practices of physicians,6 ° the influence of the pharmaceutical
model on biomedical research is perhaps more profound. Based on this
cultural outlook, the biomedical research enterprise is predominantly
focused on understanding genetics and biology with an eye toward
identifying molecular targets for drug development; at least, that is the
rationale often put forth to justify research projects.61
While developing novel pharmaceuticals is certainly a worthwhile
pursuit, increasingly the result of genetic research supports an antipharmaceutical model; i.e., a genetic test may determine which drugs an
individual should avoid taking.62 Thus, while there is much excitement
about pharmacogenomics-the ability to match drug treatments to a
particular individual's genotype-it is unclear how the pharmaceutical
industry, which makes money by selling as much of a drug as possible to
the largest number of patients, will deal with a model which decreases its
market share.63 It is very difficult to get a pharmaceutical company
executive excited about
a genetic test that promises to reduce the demand
64
product.
her
or
for his
III. PATENT BARRIERS:
A. To Patent or not to Patent?
As researchers identify novel mutations, the question becomes whether
patent applications are worth pursuing. The exclusive rights that patents
65
provide are required for successful completion of translational research.
But what exactly should be patented, and when? Although those who
pursue patents on early research results hope to share in downstream
product development by virtue of so called "reach-through" claims, authors
in the legal community have narrowly defined such claims.6 6
We published the results of our study (to discover tyrosine kinase

industrial, rather than scientific or public health concerns. Id. at 10-11.
60. See, e.g., P. Komesaroff, Ethical Issues in the Relationships Involving Medicine and
Industry: Evolving Problems Require Evolving, 35 INTERNAL MED. J. 203, 203-05 (2005).
61. See, e.g., Elizabeth lons et al., Utilizing RNA Interference to Enhance Cancer Drug
Discovery, 6 NATuRE REVIEWS DRUG DISCOVERY 556, 556 (2007).
62. See Andrew Pollack, Patient's DNA May Be Signal to Tailor Medication, N.Y.
TIMES, Dec. 29, 2008, at Al
63. See id.
64. Id.
65. See USPTO, General Information Concerning Patents, http://www.uspto.gov/web/
offices/pac/doc/general/index.html#patent (last visited Feb. 9, 2009).
66. Stephen G. Kunin et al., Reach-Through Claims in the Age ofBiotechnology, 51 AM.
U. L. Rv. 609, 638 (2002).
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mutations in AML) in a scientific journal, which are also available via open
access and are in the public domain.67 We did not pursue patent rights for
our initial findings for several reasons. First, our group is currently
committed to a purely academic open source model where we view our
mission as providing these data for the public domain. Second, however,
the utility of our findings is unclear. Although we believe that there is some
scientific value for the variants that we have identified in AML,6 8 the
clinical utility of these findings is currently unknown. One approach would
direct us to stay within the traditional academic model, and not attempt to
commercialize our findings. 69 On the other hand, it is explicitly clear from
the National Institutes of Health research agenda that practical application is
expected from the investment in medical genetic research.7 ° Since the
Constitution gives Congress the power to enact statutes that define the
intent of intellectual property law to facilitate useful business innovation, 7'
it seems that it is not a question of whether to pursue patents for our tests,
but rather where in the research process we should consider them. Thus
ensues a lively debate on the role of patent law in facilitating innovation.
Generally, the Court of Appeals for the Federal Circuit is responsible for
interpreting patent law in this country, and has been noted to consistently
favor strengthening intellectual property rights over the past several
decades.72 Recently, however, a number of experts in this field have
challenged the wisdom of pursuing strong IP rights too early in the research
process.7 3 In the related field of biotechnology, some have argued that
strong reach-through IP rights, for example, drug targets or molecular
receptors would dissuade "me-too" drug development; consequently, they
argue, the focus of biotech research would shift to the development of
breakthrough pharmaceuticals and first-in-class applications.7 4 Some legal
practitioners, in sharp contrast, have suggested that reach-through claims

67. See Tomasson et al., supra note 3, at 4801; NCBI, Gene Expression Omnibus
(GEO), http://www.ncbi.nlm.nih.gov/geo/ (enter "GSE10358" in the "GEO accession" field)
(last visited Apr. 25, 2009).
68. Tomasson et al., supra note 3, at 4803.
69. Here, I use the phrase "traditional academic model" to refer to an old-fashioned preBayh-Dole era role of the university as an engine of scholarly pursuit to the exclusion of the
pursuit of profit, or practical application. See generally BOK, infra note 85.
70. National Human Genome Research Institute, Clinical Research Program Overview,
http://www.genome.gov/1 0000331 (last visited Mar. 13, 2009).
71. U.S. Const. art. 1,§ 8, cl. 8.
72. See Michael A. Carrier, Cabining Intellectual Property Through a Property
Paradigm,54 DuKE L.J. 1, 16-17 (2004).
73. See JAMES BOYLE, THE PUBLIC DOMAIN: ENCLOSING THE COMMONS OF THE MIND

160-68 (2008), availableat http://thepublicdomain.org/thepublicdomain1.pdf.
74. Robert A. Bohrer, Reach-Through Claims for Drug Target Patents: Rx for
PharmaceuticalPolicy, 26 NATURE BIOTECHNOLOGY 55, 56 (2008).
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must meet extremely stringent criteria in order to be successful.75 These
commentators advocate increasing the stringency of such criteria because
they believe reach-through claims are inconsistent with a central tenet of
IP-promoting science by granting exclusive property rights.76
Identification of molecular receptors and pathways can be viewed
somewhat
differently as medical genetic testing certainly, but parallels
77
remain.
B. Academia and the Culture of Secrecy
If the private sector has yet to figure out successful solutions to medical
genetics testing, what roadmap can be found in the academic culture? The
view from within medical schools reveals two poles of thinking regarding
the privatization of knowledge. A "culture war" may be too dramatic a turn
of phrase, but certainly distinct subcultures are discernible within academia.
The first, and perhaps most basic approach, is the open access to knowledge
generation that can be found in some circles; for example, the DNA
sequencing arena developed some guiding principles stating that during the
heavy competition for sequencing milestones, the sequence data would be
made public.7 8
The second culture, in essence, values exclusive rights and secrecy as a
way to facilitate greater benefit to society from medical research generally.
The Bayh-Dole Act of 1980 was passed "to promote collaboration between
commercial concerns and nonprofit organizations including universities. 79
This statute gives universities IP rights over their inventions, with the hope
75. See Kunin et al., supra note 66, at 638.
76. Id. An exhaustive study of the effects of IP practice and genomic research
concluded that "the licensing of some gene-based diagnostic tests does appear to [have] an
inhibiting effect on research and related clinical practice." BD. ON SCI., TECH., & ECON.
POLICY, REAPING THE BENEFITS OF GENOMIC AND PROTEOMIC RESEARCH: INTELLECTUAL

PROPERTY RIGHTS, INNOVATION, AND PUBLIC HEALTH- 131 (2006).

Interestingly, although
insufficient evidence was found for a genetic research patent thicket, the lack of researcher
constraint was associated with a research community largely ignorant of salient IP issues.
Id. A follow-up report commissioned by the Secretary of the U.S. Department of Health and
Human Services (HHS) concluded that, unlike in other fields, patents "do not serve as
powerful incentives for either genetics research in the diagnostic arena or development of
genetic tests." SECRETARY'S ADVISORY COMM. ON GENETICS, HEALTH, & SOC'Y, PUBLIC
CONSULTATION DRAFT REPORT ON GENE PATENTS AND LICENSING PRACTICES AND THEIR
IMPACT ON PATIENT ACCESS TO GENETIC TESTS 110 (2009).

77. Just as the identification of a receptor in a biological assay may be used as the basis
for a "reach-through" claim against a drug targeting that receptor, the mutations or SNPs can
be identified before a clear understanding of how these finding will be practically useful in
medical practice.
78. National Human Genome Research Institute, NHGRI Policy for Release and
Database Deposition of Sequence Data, http://www.genome.gov/pfv.cfm?pagelD=10000910
(last visited Mar. 13, 2009).
79. Bayh-Dole Act, 35 U.S.C. § 200 (2006).
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that an increased stake in the profits will motivate universities to maximize
Essentially, therefore,
commercial applications of their research. 80
Congress has given a green light to, and has encouraged an alternative
university culture which focuses attention on entrepreneurial activities. 8'
Indeed, some university researchers view involvement with privatization
and commercial applicability of their research as the upper echelon of
medical academic success.
The debate within medical academia has somewhat paralleled the debate
in legal circles regarding the merits of strong IP rights versus a
noncommercial, purely scientific approach.82 While the purely basic
science/academic approach seeks to continue to gather more information
through research so that commercial applications can be developed,
statutory and ethical obligations require that we work actively to develop
useful clinical applications in addition to collecting genomic data. And so
we return again to the salient question, which is not whether to pursue IP
rights, but how to pursue them, and where they should fit into the research
agenda.
A certain amount of "secrecy culture" is unavoidable in competitive
scientific enterprises where credit and accolades are awarded to individuals
for scientific innovation.83 Scientists do not want to lose recognition for
long years of labor by being scooped by the competition. 84 The Bayh-Dole
Act has nurtured the competitive urges of scientists, allowing strong IP
culture to flourish within academic medicine while eroding the public
domain.8 5 Thus, aside from creating a patent thicket 86 problem, the BayhDole Act also may have reduced a potentially important source of creativity
and innovation.8 7
80. Id.
81. See, e.g., Technology Transfer Commercialization Act of 2000, H.R. 209, 106th
Cong. (2000) (enacted) (amending the Bayh-Dole Act).
82. See generally, e.g., Arti Kaur Rai, Regulating Scientific Research: Intellectual
PropertyRights and the Norms of Science, 94 Nw. U. L. REV. 77, 78 (1999) (applying the
law-and-norms theory to the study of scientific research and arguing that legal change has
been insufficient to maximize the central goals of intellectual property rights).
83. See id. at 92.
84. Id.
85. See Zhen Lei et al., Patents Versus Patenting: Implications of Intellectual Property
Protectionfor Biological Research, 27 NATURE BIOTECHNOLOGY 36, 39 (2009); see also
DEREK BOK, UNIVERSITIES IN THE MARKETPLACE: THE COMMERCIALIZATION OF HIGHER

EDUCATION 64, 143 (2003).
86. Defined, colloquially, as "a dense web of overlapping intellectual property rights
that a company must hack its way through in order to actually commercialize new
technology." Carl Shapiro, Competition Policy Ctr., Working Paper No. CPCOO-11,
Navigating the Patent Thicket: Cross Licenses, Patent Pools, and Standard-Setting 2 (2000).
87. See Lei et al., supra note 85, at 39. Empirical evidence for an anti-commons effect
in biotechnology research has been subtle, but a recent survey of academic researchers in the
agricultural sciences revealed strong beliefs among researchers that patents do inhibit
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C. The CurrentModel Does Not Appear to be Working
A recent medical sequencing project that examined the genomics of
patients with acute myelogenous leukemia (AML) provides a useful
example of the unexpected complexity of human genomes, and will be used
to illuminate roadblocks to the practical application of genomic
knowledge.88 AML was chosen because current therapies are successful in
only half of patients under the age of sixty-five, and these therapies have
not been significantly improved in the past four decades of determined
effort. 89 The intent behind sequencing the genomes of patients with AML
was to uncover mutations that form the
basis of novel diagnostic tests and
90
therapies.
pharmacologic
for
the target
Mutations known previously to occur in AML were identified at
expected frequencies, validating the high-volume re-sequencing approach. 91
While four novel somatic mutations were identified, the most dramatic
finding was the large amount of normal sequence in these cancer patientsin other words, a lack of "useful mutations. 92
Researchers conducting tissue banking studies have ethical obligations
not only to prevent harm to patients, but also to derive some societal benefit
from the genetic information obtained from patient materials. Previous
studies in AML, and preliminary studies from these samples, demonstrate a
complexity that confounds our initial goal of identifying a small number of
extremely informative mutations.93 Rather, what we are finding is that both
germline and somatic mutations may be cooperating in a subtle fashion to
give rise to disease.94
Our finding of unexpected changes in the skin DNA of our patients
(changes they were born with) led us to consider the possibility that these
changes contributed to a predisposition
toward the development of
leukeia
atents 95
leukemia in or
our patients.
Such variations, single nucleotide
polymorphisms, most often are of no significance whatsoever, but a small
subset of such variants, or alleles, have been found to be statistically
associated with disease development.
Despite powerful statistical

scientific research. Id.
88. Tomasson et al., supra note 3.
89. See generally Asa Rangert Derolf et al., Improved Patient Survival for Acute
Myeloid Leukemia: A Population-Based Study of 9729 Patients Diagnosed in Sweden
Between 1973 and 2005, 113 BLOOD 3666, 3666 (noting that while AML survival has
improved during the last decades, the majority of AML patients die of their disease).
90. See Tomasson et al, supra note 3, at 4797.
91. Id. at 4803.
92. Id.
93. See, e.g., Tomasson et al., supra note 3.
94. Id. at 4804-07.
95. Id.at 4798.
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96
association, most alleles imply only a small increase in relative risk.
Homozygosity, (i.e. two copies of a risk allele) may increase risk yet
further, 97 but still not provide a large enough increase in risk to be useful to
patients or physicians.
Can we look to the private sector for a roadmap on how to perform
human genetics usefully in the 21st century? deCODE genetics, Inc.,
through a unique arrangement with the Icelandic public and health care
system, is arguably the world leader in human medical genetics. 98 deCODE
has published dozens of high-profile scientific articles describing germline
variations that predispose individuals to cancer, heart disease, and common
neurological diseases.9 9
Compared to our small university study,
deCODE's efforts are comprehensive, large-scale, and extremely
farsighted. 00 In addition to its discovery work, deCODE offers genetic
testing for the alleles it and others have discovered, and deCODE is
developing novel pharmaceutical compounds targeted to the gene products
it has identified in the screening process.1 ' In this way, deCODE stands as
an example for us to follow.
However, in the face of soaring academic success, the business model of
deCODE is on the verge of complete failure.10 2 As of this writing, the stock
price of deCODE genetics is in the vicinity of $0.20 per share, very near its
fifty-two week low. 10 3 The general stock market decline in 2008 certainly
contributed, but deCODE's stock price has been falling for several years,
with a steady downward trajectory.1 °4 The market capitalization of
deCODE is approximately $12 million, which appears to be an extremely
small sum to pay for one of the leaders in medical genetics, but due

96. See id. at 4803-05.
97. See Kristleifur Kristjansson et al., Linkage of Essential Hypertension to
Chromosome 18q, 39 HYPERTENSION
1044, 1044-49 (2002), available at
http://hyper.ahajournals.org/cgi/reprint/39/6/1044.
98. deCODE genetics, About deCODE genetics, http://www.decode.com/Company/
Index.php (last visited Apr. 5, 2009).
99. A complete listing of these publications is available on the deCODE website.
deCODE genetics, Publications, http://www.decode.com/Publications/Index.php (last visited
Apr. 5, 2009).
100. See deCODE genetics, http://www.decode.com/ (last visited Apr. 5, 2009).
101. Id.; see also deCODE genetics, Using Genetics to Empower Prevention of
Common Diseases, http://www.decode.com/From-Genes-to-Drugs.php (last visited Mar. 14,
2009); deCODE genetics, Drug Discovery, http://www.decode.com/Drug-Discovery.php
(last visited Mar. 14, 2009).
102. See Meredith Wadman, Icelandic Biotech Feels the Pinch, 455 NATURE 842, 842
(2008).
103. NASDAQ,
DCGN:
Stock
Quote
and
Summary
Data,
http://quotes.nasdaq.com/asp/SummaryQuote.asp?symbol=DCGN&selected = DCGN (last
visited Apr. 5, 2009) (52-week low is $0.15 per share).
104. Wadman, supra note 102, at 842.
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diligence finds that deCODE has a large debt
burden, which potential
05
with.1
deal
to
have
would
owners
and
managers
In 2009, it is highly probable that deCODE will become insolvent and
will either declare bankruptcy or be bought outright by a larger
pharmaceutical company.10 6 What should we take from the fact that this
scientifically outstanding company faces financial crisis? Despite fulfilling
the ultimate goal of identifying dozens of extremely informative SNPs, and
developing clinical tests for these mutations as well as novel
pharmaceutical compounds, deCODE's business model is unsuccessful.
deCODE's diagnostic model has not yet succeeded because of the gap
between the powerful statistical significance of the SNPs deCODE has
discovered and the lack of practical predictive significance of these
findings. Searching the United States Patent and Trademark Office
database for "deCODE Genetics" as the assignee pulls up twenty-three
issued patents and sixty pending patent applications including issued
patents for "human narcolepsy gene" and "osteoporosis gene." Defining IP
for such genetic information has not proved very useful. The second aim of
their strategy is to develop drugs targeting the cellular pathways implicated
by the DNA findings, and the company may yet find commercial success
with more traditional drug structure IP. The story of deCODE is a
cautionary tale, and highlights the difficulties involved with translating
basic laboratory success into clinically useful, commercially viable practice.
IV. OTHER POTENTIAL BARRIERS

A. Effects of Medicare Legislationon DiagnosticTesting Research
Healthcare policy also presents a hurdle in the effort to identify DNA
markers that can be used as the basis for novel and useful clinical tests. For
instance, the language of Medicare's "Reasonable and Necessary" clause
defines the landscape of clinical research, and may affect the development
of genomic tests by outlining which tests will be reimbursed by health
insurance. Medicare's enabling legislation states that "[n]o payment may
be made ...for any expenses incurred for items and services that are not
reasonable and necessary for the diagnosis or treatment of illness or
injury."' 107 New genetic tests with potential utility are considered
experimental, and may not be covered by medical insurance until they
105.

Id.; NASDAQ, supra note 103.

106.

Meredith Wadman, Gene-Testing Company Fights to Retain Listing, NATURE

NEWS, Nov. 11, 1008, http://www.nature.com.flagship.luc.edu/news/2008/08111 1/full/
news.2008.1220.html.
107. Social Security Act of 1965 § 1862(a)(1)(A) (current version at 42 U.S.C. §
1395y(a)(1)(A) (2006)).
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prove sufficiently safe and effective to be considered reasonable and
necessary. 108
Healthcare policy has set a high bar for genomic tests. Genetic tests
performed "in the absence of signs, symptoms, complaints, personal history
of disease, or injury are not covered except when there is a statutory
provision that explicitly covers tests for screening."' 10 9 Even for tests that
the research community considers "home runs," Medicare requires a long
process to establish that they are reasonable and necessary.1 0 In 1994, an
international mapping effort identified inherited mutations in the BCRA1
and BRCA2 genes, which confer a high risk for the development of breast
and ovarian cancer."' Researchers identified BRCA1 and BCRA2 using
classical genetic techniques, including positional cloning, to identify genes
in association with a clear heritable phenotype."12 The degree to which
BRCA1 and BRCA2 accounted for the heritable phenotype was
unexpectedly low.113 Very few patients with strong familial cancer histories
have mutations in BRCA1 or BRCA2. ll4 This gap has been referred to as
"missing heredity" and has been observed in numerous studies looking for
genetic markers for heritable health traits."5
The identification of the BRCA1 and BRCA2 genes was a scientific
tour-de-force. Soon after this effort, clinical tests for these genes became
available which enable clinicians to identify whether an individual is
strongly predisposed to develop breast or ovarian cancer. 16 Yet health
108. See generally Ctrs. for Medicare & Medicaid Servs., Transcript from Medicare
Evidence Development and Advisory Committee Meeting (Feb. 25, 2009) [hereinafter
Advisory Committee Meeting] (discussing the merits of diagnostic use of genetic testing and
whether it improves health outcomes for Medicare beneficiaries).
109.

CTRS. FOR MEDICARE & MEDICAID SERVS., PUB. No. 100-04, MEDICARE CLAIMS

PROCESSING MANUAL ch. 16, § 120.1 (2009), http://www.cms.hhs.gov/manuals/downloads/
clml04cl6.pdf; CTRS. FOR MEDICARE & MEDICAID SERVS., LCD for Genetic Testing
(L24308) (2009), http://www.cms.hhs.gov/mcd/viewlcdpdf.asp?lcdid=24308&lcdversion
=10&contractor id=129; see also 42 U.S.C. § 1395y (2006); 42 C.F.R. § 410 (2008);
Medicare; Negotiated Rulemaking: Coverage and Administrative Policies for Clinical
Diagnostic Laboratory Services, 66 Fed. Reg. 58,788 (Nov. 23, 2001).
110. See id
111. P. Andrew Futreal et al., BRCA1 Mutations in Primary Breast and Ovarian
Carcinomas, 266 SCI. 120, 120-22 (1994); Yoshio Miki et al., A Strong Candidatefor the
Breast and Ovarian Cancer Susceptibility Gene BRCA 1,266 ScI. 66, 66-71 (1994).
112. Miki et al., supra note 111, at 66.
113. Id.at 70.
114. Id.
115. See Brendan Maher, The Case of the Missing Heritability, 456 NATURE 18, 18
(2008).
116. Futreal et al., supra note 11; Miki et al., supra note 111; see also NAT'L CANCER
INST., FACT SHEET: GENETIC TESTING FOR BRCA1 AND BRCA2: IT'S YOUR CHOICE 3 (2002)
[hereinafter FACT SHEET], available at http://www.cancer.gov/images/Documents/abcb7812a132-4e78-a532-f02c92fa9b9/fs3_62.pdf, Breast Cancer Action, Policy on Genetic Testing
for Breast Cancer Susceptibility, http://bcaction.org/index.php?page=genetic-testing-policy
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insurance coverage to test for BRCA1 and BRCA2 mutations was difficult

to obtain because of the need to satisfy the reasonable and necessary
clause. 1 7 The test is neither "necessary" for the diagnosis nor for the
treatment of patients with breast cancer. Rather, the utility of the test is in
identifying a small subset of individuals with a family history of breast
cancer that are at high risk for developing breast or ovarian cancer. 1 8 Once
an individual is identified as a BRCA1 gene carrier, several therapeutic
options exist, including prophylactic mastectomy and/or oopherectomy, but
the optimal approach for these patients is still evolving." 9 Additional
genomic tests are being handled on a case-by-case basis, and the criteria for
whether or not a new genomic test improves healthcare outcomes are
currently under debate. 2 °
The statutory language is written to support the use of tests in the
treatment of illnesses, but ironically, the emerging data suggest that
genomic tests create the greatest benefit for health outcomes when
performed on individuals before they develop a disease -i.e., in the design
of preventive medicine strategies. 12 ' Therefore, since federal programs do
not provide the financial support for clinical research, including the
development of genetic tests, such support
is by and large left to companies
22
profits.1
future
of
goal
the
by
motivated
The road from gene identification to covered test is a long one. In
addition to the "missing heredity," investigators must also search for the
"missing money" needed to support the development of tests on undefined
123
genetic loci to improve health care outcomes in unclear ways.

(last visited Mar. 14, 2009).
117. See FACT SHEET, supra note 116, at 7. Even if a person has private insurance
coverage for such testing, many prefer to pay out-of-pocket to prevent insurers from
practicing genetic discrimination by increasing premiums or canceling coverage based on a
positive test for the BRCA 1 or BRCA2 alteration. Id.; see also Mum J. Khoury et al., The
Evidence Dilemma in Genomic Medicine, 27 HEALTH AFrr. 1600, 1600 (2008) (discussing
the need for a balance between genomic testing innovation and reasonable evidence
thresholds to move new technology into clinical practice).
118. Heidi D. Nelson et al., Genetic Risk Assessment and BRCA Mutation Testingfor
Breast and Ovarian Cancer Susceptibility: Systematic Evidence Review for the US.
Preventive Services Task Force, 143 ANNALS INTERNAL MED. 362, 363 (2005).
119. Dinitrios H. Roukos & Evangelos Briasoulis, Individualized Preventive and
Therapeutic Management of Hereditary Breast Ovarian Cancer Syndrome, 4 NATURE
CLrNICAL PRAC. ONCOLOGY 578, 580-87 (2007).
120. See Advisory Committee Meeting supra note 108.
121. See LCD for Genetic Testing, supra note 109.
122. See Gillian Haddow et al.,
Tackling Community Concerns About
Commercialisation and Genetic Research: A Modest InterdisciplinaryProposal, 64 Soc.
SCl. & MED. 272, 273 (2007).
123. See Maher, supra note 115, at 19 (noting that enthusiasm to complete studies on
missing heritability should increase as the costs of sequencing decrease).
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B. Effects of HIPAA on Genomic Research

The Health Insurance Portability and Accountability Act (HIPAA) of
1996 modified the Medicare legislation in ways that affect clinical research,
and may profoundly affect the process of developing genomic tests. 124 The
law was intended to improve Medicare and Medicaid statutes, with an eye
toward preventing unintended harm that may be inflicted by the
dissemination of personal patient information. 25 HIPAA aimed to allow
individuals to maintain their employer-provided health insurance coverage
as they changed jobs. 126 To counter concerns that sensitive medical
information could be inappropriately (and easily) disclosed through the use
of electronic medical records (EMR), HIPAA required the Secretary of
Health and Human Services (HHS) to develop regulations to prevent such
disclosure. 127 Therefore, the Privacy Rule emerged in 2000, and was
amended in 2002, to prevent inappropriate transfer or disclosure of
protected health information (PHI). 128 Notably, HIPAA does not identify a
patient "right to privacy," rather the Privacy Rule restricts the ways that
covered entities may use clinical data. 129 The Privacy Rule provides civil
and criminal penalties for the unlawfully using, obtaining or disclosing
protected patient information in electronic or other formats 30 and has given

rise to a significant bureaucracy dedicated to ensuring that policies and
3
procedures are compliant with the regulations embodied in the law.1 '
In addition to the Privacy Rule, HHS adopted the Security Rule in 2003
to set specific standards which covered entities must follow to protect

124. See generally Health Insurance Portability and Accountability Act of 1996, Pub. L.
No. 94-101, 110 Stat. 2033 (requiring the Secretary of Health and Human Services to
develop recommendations regarding the uses and disclosure of individually identifiable
health information).
125.

See CTRS. FOR MEDICARE & MEDICAID SERVS., Health Insurance Portability and

Accountability Act of 1996: Summary of Administrative Simplification Provisions,
http://www.cms.hhs.gov/HIPAAGenlnfo/Downloads/SummaryofAdministrativeSimplificati
onProvisions.pdf (last visited Mar. 14, 2009).
126. See Health Insurance Portability and Accountability Act of 1996, Pub. L. No. 104191, § 101, 110 Stat. 1936, 1942 (1996).
127. Id. § 264.
128.
U.S.
INFORMATION

DEPT. OF HEALTH & HUMAN SERVS., PROTECTING PERSONAL HEALTH
IN RESEARCH: UNDERSTANDING THE HIPAA PRIVACY RULE 2 (2003)

[hereinafter

UNDERSTANDING

THE

HIPAA

PRIVACY

RULE],

http://privacyruleandresearch.nih.gov/pdf/HIPAABooklet_4-14-2003.pdf,
C.F.R. § 160 (2008).
129.

available

see

at

also 45

See, e.g., UNDERSTANDING THE HIPAA PRIVACY RULE, supra note 128 at 5.

A

covered entity is defined as a health plan, a health care clearinghouse, or a health care
provider who transmits health information electronically. 45 C.F.R. § 160.103 (2008).
130.

E.g., UNDERSTANDING THE HIPAA PRIVACY RULE, supra note 128, at 2.

131. See, e.g., Washington University in St. Louis, HIPAA Privacy
https://secpriv.wusm.wustl.edu/privacy/default.aspx (last visited Apr. 23, 2009).

http://lawecommons.luc.edu/annals/vol18/iss2/5

Office,

20

2009]

Tomasson: Legal, Ethical, and Conceptual Bottlenecks to the Development of

Bottlenecks to the Development of Useful Genomic Tests

251

PHI. 132 Compliance with the Security Rule includes, but is not limited to,
mandatory training and compliance modules that healthcare providers must
complete, locking the doors of rooms and cabinets that contain any patient
information, and ensuring that every computer, handheld PDA and mobile
phone capable of receiving clinical data in any form (e.g. email) is user
restricted and password protected. 33 Whether the HIPAA bureaucracy
impedes clinical research in any significant way is unknown. The intention
of HIPAA was not to impede medical research, and PHI can be used in
medical research in compliance with the Privacy Rule by eliminating
34

specific data that might be used to personally identify study subjects.
including
Such "de-identification" includes eliminating eighteen identifiers,
35
name, address, and other individually identifiable information.'
Recent technical developments (e.g. whole genome sequencing) have
made HIPAA statutory compliance for covered entities more complex by
generating PHI that resist de-identification.136 As the genetic resolution of
newer studies has increased dramatically, the standard methods for ensuring
that medical research using patient samples is compliant with HIPAA by
de-identifying samples has become nearly impossible because the genomic
data .itself can be used to determine individual identity.' 37 With high
throughput sequencing technology, we now have the new situation of
genetic data that is detailed enough that it is inseparable from identifying
information. 138
Large resolution genome studies create genetic fingerprints that can be
used to identify the individual and cannot easily be de-identified 3 9 Deidentifying PHI by the usual means (e.g. no names, no dates of birth) may

132. Health Insurance Reforms, Security Standards, 68 Fed. Reg. 8,334 (Feb. 20, 2003);
see also 45 C.F.R. §§ 160.103, 162.103, 164.103-.318, 164.500, .501, .504 (2008).
133. 45 C.F.R. §§ 164.304, .306, .308, .310, .312 (2008).
134. 68 Fed. Reg. 8,338 (Feb. 20, 2003); see also UNDERSTANDING THE HIPAA PRIVACY
RULE, supra note 128, at 9-10.
135. 45 C.F.R. § 164.514(b)(2)(i) (2008).
136. See generally William W. Lowrance, Nat'l Human Genome Research Inst.,
Privacy, Confidentiality, and Identifiability in Genomic Research 5-6 (2006) (discussion
document for Human Genome Research Institute, Oct. 3 to 4, 2006) (discussing the
challenges involved in simultaneously protecting individual privacy and fostering genomic
research, including strategies for identifying, as well as de-identifying genomic data),
http://www.genome.gov/Pages/About/OD/ReportsPublications/IdentifiabilityWorkshopWhit
ePaper.pdf.
137. See id. at 12-20 (discussing various strategies for identifying non-identified
genomic data and for de-identifying genomic data).
138. Cf id. at 5 ("The NHGRI Medical Sequencing Program and many other projects
will ...

generate data that are ...

person-specific, [will] categorize many data with respect

to ... disease diagnosis... [and will] maintain links, at least indirectly, to clinical, family,
.
social, and demographic data .
139. Id. at 6.
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be insufficient for HIPAA compliance. 40 Our institution is pursuing
sequencing studies with revised patient consent forms addressing privacy
issues.
Also, PHI may be used in medical research without deidentification, but this requires an authorization in addition to and separate
from informed consent.1 41142 Such authorization allows the use of PHI for
specific research projects.
Although surmountable, privacy issues are likely to remain significant,
and may change the landscape of genomic efforts. Early genetic marker
studies accessed a limited amount of patient information, such as type of
cancer or overall survival. However, as the search intensifies for useful
genetic markers, patient clinical data with the greatest possible depth will be
required, e.g. detailed family histories, employment and environmental
histories, and reactions and responses to medications. 143 Currently, this
type of data is extremely unwieldy, both difficult to collect and difficult to
access using traditional paper medical records. 144
The Obama
administration plans a large effort to use information technology to improve
the efficiency of healthcare delivery in the United States.1 45 In addition to
efficiency, an electronic medical data system would provide a powerful tool
for genomics researchers looking for correlations between genetic markers
and important health parameters. 46 However, lawmakers must contend
with discordance between the healthcare industry and consumer groups that
disagree about whether
HIPAA regulations are satisfactory to safeguard
147
patient confidentiality.
HIPAA prohibits the sharing of personal health information by providerbased research programs (covered entities). 48 Privacy protection for
140.
141.
142.

Cf id. (noting that current protections for de-identification are inadequate).
45 C.F.R. § 164.506(b)(2), 508(a)(1) (2008).
45 C.F.R. § 164.508(b)(1)(i),.508(b)(3)

(2008).

143. See generally Berrie Rebecca Goldman, Pharmacogenomics:Privacy in the Era of
PersonalizedMedicine, 4 Nw. J. TECH. & INTELL. PROP. 83, 84, 87, 88, 91 (2005) (explaining

the need for a comprehensive database containing genetic profiles, as well as patient
outcomes and side effects, and proposing federal legislation to expand HIPAA to protect
such information).
144. See generally Karoline Kreuser, Introduction, The Adoption of Electronic Health
Records: Benefits and Challenges, 16 ANNALS HEALTH L. 317, 319 (2007).
145. Robert Pear, Privacy Issue Complicates Push to Link Medical Data, N.Y. TIMEs,

Jan. 18, 2009, at A16.
146. E.g., Goldman, supra note 143, at 90 ("Pharmacogenomics cannot succeed unless a
system is developed where a large number of genetic profiles and individual responses to
drugs may be compared to evaluate drug efficacy and potential adverse reactions.").
147.

Pear, supra note 145; Patient Privacy Rights, HIPAA - The Intent vs. The Reality,

http://www.patientprivacyrights.org/site/PageServer?pagename=HIPAAIntentVsReality
(last visited Apr. 17, 2009).
148. 45 C.F.R. § 160.102, .103; see also U.S. DEPT. OF HEALTH & HUMAN SERVS.,
SUMMARY OF THE HIPAA PRIVACY RULE, at 2-4 (2003), available at http://www.hhs.gov/

ocr/privacy/hipaa/understanding/summary/privacysummary.pdf.
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patient data is likely to get even stronger with the federal push for a
nationwide EMR system, 49 and therefore genomic research approaches
150
using commons or network-based approaches must be used with caution.
However, with patient consent and authorization, research groups can
obtain exceptions to the HIPAA Privacy Rule.' 5' Genomic research
performed by medical schools can proceed in compliance with HIPAA's
regulatory hurdles.' 52 On the other hand, institutions that are not HIPAA
covered entities (e.g. business schools, private non-healthcare corporations)
do not face these regulatory constraints and may be more efficient at
genomic research in the years ahead. 153 By regulating the playing field,
HIPAA regulations may inadvertently influence where genomic research is
conducted. HIPAA's provider-specific regulatory schema makes it easier
for non-provider groups to analyze patient health information using novel
open network strategies. We should not be surprised if Google 54 or
23andMe, a retail DNA test provider, are able to extract important data.'
C. The Absence of PatientRights
The Privacy Rule and informed consent requirement codify ethical
norms that govern human subject research, but patients in tissue banking
and analysis studies are provided no specific rights. 55 Researchers will
149. President Obama recently signed the American Recovery and Reinvestment Act of
2009, which appropriated $1.5 billion for investment in health information technology
systems. Pub. L.No. 111-5, 123 Stat. 115, 175. In addition, the HITECH Act is intended to
promote health information technology and includes new standards for electronic health
records. HITECH Act, Pub. L. No. 111-5, 123 Stat. 226 (2009).
150. See generally Patient Privacy Rights, Legislation, http://www.patientprivacyrights.
org/site/PageServer?pagename=Legislation (last visited Apr. 17, 2009).
151.

45 C.F.R. § 164.508; UNDERSTANDING THE HIPAA PRIVACY RULE, supra note 128,

at 9-18.
152.

UNDERSTANDING THE HIPAA PRIVACY RULE, supra note 128, at 128.

153. Non-healthcare organizations, such as business schools and corporations, are not
covered entities under HIPAA and therefore are not subject to the regulations. See 45 C.F.R.
§ 160.103 (2008). However, such an organization might be a "business associate" (BA)
under HIPAA if it receives individually identifiable health information from a covered entity
(or another BA) for use in its research. Id. The BA must sign an agreement with the
covered entity which requires the BA to implement appropriate safeguards under the
Recent
Security Rule. 45 C.F.R. § 164.308, .314, .502(e)(1), .504(e)(1), (2008).
amendments to HIPAA now subject BAs to the Privacy and Security Rules. HITECH Act
§§ 13400-08, 123 Stat. at 258-71. Further, the HITECH Act requires the Secretary of Health
and Human Services (and the Federal Trade Commission) to produce a report to determine
whether security and privacy provisions are necessary for non-covered entities that access
information held in personal health records. Id. § 13424(b).
154. See generally Anita Hamilton, The Retail DNA Test: Invention of the Year, TIME,
Nov. 10, 2008, at 68, 68-70 (describing 23andMe, a company providing a $399 saliva test
that identifies and interprets 600,000 genetic markers and can identify a person's
predisposition for over ninety traits).
155. 45 C.F.R. § 46.101(b)(4) (2008) (exempting studies from the HHS Policy for the
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require more participation and access to more detailed PHI, with the
hopeful goal of developing useful (and profitable) diagnostic tests, but
patients have no ownership rights to their own tissue, regardless of its
potential value. 156 The patients who provide informed consent and agree to
participate in research studies are told that they will neither profit nor
benefit from their participation, and they may incorrectly assume the same
is true for the doctors and scientists performing the research. 57 Greenberg
v. Miami Children's Hospital involved a group of parents with children
afflicted with Canavan disease. The parents were stunned to learn that
researchers, using tissue samples taken from the children, developed a
diagnostic test for Canavan disease and obtained the exclusive patent rights,
thereby restricting its availability. 158 The court held that the families had no
ownership stake or control over the IP of the test whose creation they had
facilitated.' 59
The perception that the legal framework for distributing profits from a
hypothetical "home run" test is unethical may be preventing efficient
discovery and development.' 60 Diamond v. Chakrabartyestablished that
that genetically engineered bacteria, in essence living things, can possibly
be patented which opened the door to other biological patients. 161 However,
courts have consistently applied the doctrine of simultaneous conception
and reduction to practice as a prerequisite to claim inventorship. 162 The
Protection of Human Research Subjects, including exemption from informed consent
requirements, if the "[r]esearch involv[es] the collection or study of existing data,
documents, records, pathological specimens, or diagnostic specimens.., if the information
is recorded by the investigator in such a manner that subjects cannot be identified, directly or
through identifiers linked to the subjects."); cf 45 C.F.R. § 164.512(h) (2008) ("A covered
entity may use or disclose protected health information to ... entities engaged in the
procurement, banking, or transplantation of... tissue for the purpose of facilitating...
donation and transplantation."); see also Donna M. Gitter, Ownership of Human Tissue: A
Proposalfor Federal Recognition of Human Research Participants' Property Rights in
Their Biologic Material,61 WASH. & LEE L. REv. 257, 285 (2004).
156. Gitter, supra note 155, at 319-320, 327, n.295; Moore v. Regents of the Univ. of
Cal., 793 P.2d 479, 492-93 (Cal. 1990).
157. Cynthia M. Ho, Who Deserves the PatentPot of Gold? An Inquiry into the Proper
Inventorship of Patient-BasedDiscoveries,7 DEPAUL J. HEALTH CARE L. 185, 199 (2004).
158. Greenberg v. Miami Children's Hosp. Res. Inst., Inc., 264 F. Supp. 2d 1064, 106667 (S.D. Fla. 2003). Over the course of seven years, the plaintiffs provided tissue and blood
samples, including a tissue sample of their son's organs after his death from Canavan
disease. Jd.
159. Id.at 1074-76.
160. See Ho, supra note 157, at 199-201.
161. Diamond v. Chakrabarty, 447 U.S. 303 (1980), affg In re Bergy, 563 F.2d 1031
(C.C.P.A. 1977), affig 596 F.2d 952 (C.C.P.A. 1979) (holding that genetically engineered
organisms are patentable subject matter within the plain language of the Patent Act); Ho,
supra note 157, at 201.
162. E.g., Brown v. Regents of the Univ. of Cal., 866 F. Supp. 439, 442-43 ("Under the
doctrine of simultaneous conception and reduction to practice, the Federal Circuit has held
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conception element "requires both the idea of the invention's structure and
possession of an operative method of making it."' 163 Patients who are tissue
donors, as in Greenberg, are not co-inventors even though they may have
originally envisioned the diagnostic test that resulted from their donations,
and had intended that the test be freely available.' 64 Further, the court in
Buildex, Inc. v. Kason Industries found that recognizing
a problem is also
165
insufficient to state a valid co-inventorship claim.
The analysis of patient tissue banks is not wholly dissimilar from the
concerns of "bio-piracy" of Indigenous Populations.166 Researchers may be
"genetic gold diggers," but courts consider allegations of fraud in such
cases to be "much-abused and too often last-resort allegation[s].' 67
V. NEW APPROACHES: CREATIVE COMMONS AND OPEN SOURCE
The human genome has become cluttered with patents, and patent
ownership is often fragmented, raising the possibility that access may be
limited by complex licensing agreements. 168 Some argue that the patent
system should be abolished. 69 While outright abolition might be too
170
drastic, clearer outlines of patent "property" and transparency are needed.
One goal is to find a way to sift genomic data for the "gold nuggets" of
useful data without contributing to patent thickets. Another point to
consider is whether we can allow patient-participants an ownership stake in
the search to encourage greater participation in genomic research projects.
The UK Biobank is a large scale tissue banking and research effort
funded by the Wellcome Trust. 171 UK Biobank Ltd. is a charitable
that complex chemical compounds are not conceived until they have been reduced to
practice.").
163. Id. (quoting Amgen, Inc. v. Chugai Pharm. Co., 927 F.2d 1200 (Fed. Cir. 1991).
164. See, e.g., Greenberg, 264 F. Supp. 2d at 1067, 1074.
165. Buildex, Inc. v. Kason Indus., 849 F.2d 1461, 1464-66 (Fed. Cir. 1988).
166. See generally Ho, supra note 157, at 235-42 (discussing "bio-piracy," where those
who provide raw materials that result in the production of patentable material are denied
patent rights).
167. Preemption Devices, Inc. v. Minn.Mining & Mfg. Co. 732 F.2d 903, 908 (Fed. Cir.
1984); see also id. at 228.
168. Kyle Jensen & Fiona Murray, Intellectual Property Landscape of the Human
Genome, 310 ScI. 239,239 (2005).
169. See Generally Michele Boldrin & David K. Levine, Against Intellectual Monopoly
(2008) (arguing that intellectual property is not necessary to promote innovation and it
inhibits growth), availableat http://www.dklevine.com/papers/imbookfinalall.pdf.
170.
See generally JAMES BESSEN & MICHAEL J. MEURER, PATENT FAILURE: How
JUDGES, BUREAUCRATS, AND LAWYERS PUT INNOVATORS AT RISK 8-25 (2008) (suggesting

that policy reforms to improve the notice function of property to improve transparency and
create well-defined boundaries could make the United States more economically
competitive).
171. UKBiobank- What Is It?, http://www.ukbiobank.ac.uk/about/what.php (last visited
Apr. 19, 2009).
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company that exercises management oversight of UK Biobank and is the
legal owner of the database. 172 The UK Biobank rejected the idea of tissue
"ownership" for a "partnership" model, however David Winikoff, of the
University of California-Berkeley, has noted that partnership has a specific
legal meaning that is not truly relevant to the Biobank example. 173 UK
Biobank enforces certain ethical standards, such as the noncommodification of samples, and the requirement for affirmative consent,
but the research participants (tissue donors) possess little control share, and
no equity share in the common pool resource. 174 As such, the project does
not achieve its own ideals concerning
"partnership," and in so doing, loses a
75
strength.
of
source
potential
Finding value in genomic testing may be amenable to a social network
approach to value creation.176 To facilitate the discovery phase of genomic
research that is problematic using current approaches, individuals may
share their data in a creative commons.' 77 In fact, data emerging from large
78
scale sequencing efforts may be pointing toward these approaches.
Specifically, the genomic diversity that is being discovered appears to
describe a power-law distribution, 179 in that as mutations and SNP databases
increase in size, they also decrease in frequency. 80 One embodiment of a
creative commons, termed "The Long Tail," has been described as a
business model phenomenon of the internet era where companies can
aggregate niche markets. 18 ' For example, while Blockbuster Video, by
virtue of limited shelf space, deals primarily in renting "hit" movies, Netflix
has found that the bulk of its revenue results from customers renting a large
172.

UK BIOBANK, LTD., UK BIOBANK ETHICS AND GOVERNANCE FRAMEWORK 3

(version 3.0, 2007), availableat http://www.ukbiobank.ac.uk/docs/EGFlatestJan20082.pdf.
173. David E.Winickoff, Partnership in U.K. Biobank: A Third Way for Genomic
Property?, 35 J.L. MED. & ETHICS 440, 440-56 (2007).
174. Id. at 5 passim.
175. Winickoff, supra note 173, at 445.
176. YOCHAI BENKLER, THE WEALTH OF NETWORKS: How SOCIAL PRODUCTION
TRANSFORMS MARKETS AND FREEDOM 344-53 (2006), available at http://www.benkler.org/

BenklerWealthOf Networks.pdf.
177. See Lawrence Lessig, Commentary, The Creative Commons, 65 MONT. L. REV. 1,
1-14 (2004).
178. See Thomas Goetz, The Gene Collector, WIRED, Aug. 2008, at 134, available at
http://www.wired.con/images/press/pdf/genecollector.pdf.
179. Cf Lander et al., supranote 20, at 914 ("To realize the full promise of comparative
genomics, however, it needs to become simple and inexpensive to sequence the genome of
any organism.
Sequencing costs have dropped 100-fold over the last 10 years,
corresponding to a roughly twofold decrease every 18 months. This rate is similar to
'Moore's law' concerning improvements in semiconductor manufacture.").
180. Hap Map: About the Project, http://snp.cshl.org/abouthapmap.html (last visited
Apr. 19, 2009).
181. Chris Anderson, The Long Tail, WIRED, Oct. 2004, http://www.wired.comwired/
archive/12. 10/tail.html.
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variety of less-common and rare films. 1 82 Chris Anderson wrote about the
entertainment industry, noting that "[w]e're stuck in a hit-driven mindsetwe think that if something isn't a hit, it won't make money and so won't
return the cost of its production."'1 83 This language is apropos of our
genome-wide sequencing efforts in cancer. Originally, we sought to find
common, i.e. "hit" mutations, but instead uncovered rare mutations that
were initially discounted.184 If this power law distribution of mutations
holds up, and most of the mutations in different cancers are rare ones, then a
distributed approach to reverse genetic analysis (i.e. validating the clinical
or biological significance of discovered genetic changes), is almost
imperative.' 85 In the Personal Genome Project, researchers at Harvard
University Medical School are trying a cooperative approach to collecting
86
DNA samples and assembling diverse phenotype data using volunteers.
This project may point the way for future disease research.1 87 The Personal
Genome Project takes an "open source" approach to genomics research by
asking volunteers to contractually forfeit intellectual property rights by
putting their personal and genomic data in the public domain so that
research can proceed without the distractions and impediments posed by IP
concerns. Once open source mechanisms identify informative genetic loci,
patent pools or clearinghouses
may be used as mechanisms to overcome
188
remain.
any
if
thickets,
patent
PXE International provides a distinct model based on a contractual
relationship between researchers and patients to ensure that the products of
research conducted with donated tissues return benefits to patients with the
rare genetic disorder pseudoxanthroma elasticum (PXE). 189 The parents of
two children with PXE established PXE International to facilitate research
and accelerate the development of tests and treatments. 190 They recognized
that tissue donations were critical to the identification of the gene

182. Id.
183. Id.
184. Cf Anna D. Barker & Francis S. Collins, Mapping the Cancer Genome, SCI. AM.,
Mar. 2007, at 50, available at http://www.sciam.com/article.cfm?id=mapping-the-cancergenome (discussing the importance of mapping an entire human and cancer genomes to
pinpoint genes that cause cancer).
185. See Goetz, supra note 178 (explaining that disease detection and other correlations
must be derived from an entire population).
186. See Personal Genome Project, http://www.personalgenomes.org (last visited Apr.
19, 2009).
187. See id.
188. Geertrui Van Overwalle et al., Modelsfor FacilitatingAccess to Patentson Genetic
Inventions, 7 NATuRE REVIEWS GENETICS 143, 146 (2006).

189.
190.

See Gitter, supra note 155, at 315-16.
Id.
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responsible for PXE and for the success of clinical research. 191
Accordingly, they established a tissue bank that gave contractual benefits to
tissue donors, ensuring patients affordable access to tests and treatments
developed by using their samples. 9 2 This was a unique way of sharing IP
rights with patient research participation that avoided the problems that
occurred in Greenberg v. Miami Children's Hospital, but required a
substantial amount of activism and involvement on the part of patient
families. It is unclear whether this approach could be replicated with more
common diseases.
VI. CONCLUSION

What began as a straightforward idea-to sequence genes so that we may
have new genetic tests useful for improving human health-in the final
analysis turns out to be a project fraught with complexity. The passage of
the Bayh-Dole Act may have contributed to an erosion of the scientific
culture at medical schools, spurring a metamorphosis of the university from
a place of pure research and scientific inquiry to a source of valuable
intellectual property. 193 But the transformation of academic culture towards
a more corporate model is wider spread and has been underway since well
before 1980.194 Recently, something of a backlash is occurring against the
involvement of pharmaceutical companies in the process of medical
research, but response has been pallid at best. 95 It is surprising that doctors
that fail to report drug company Support, and also fail to appreciate the
domination the pharmaceutical industry has come to hold over the
fundamental model of medical research in this country. 196 Modern cancer
research is focused on the identification of genes and pathways as exciting
new drug targets, ignoring the fact that the identification of tobacco as a
carcinogen was197one of the greatest breakthroughs in cancer medicine of the
past 100 years.
Our genomes, however, have not received the drug company memos.
The glimpses we are getting of the genetic component of this disease have
191.
192.
193.

Id.
Id.
DAVID

C.

MOWERY

ET

AL.,

IVORY

TOWER

AND

INDUSTRIAL

INNOVATION:

UNIVERSITY-INDUSTRY TECHNOLOGY TRANSFER BEFORE AND AFTER THE BAYH-DOLE ACT
(2004); see also BOK, supra note 85, at 11 passim.

194.

FRANK DONOGHUE, THE LAST PROFESSORS: THE CORPORATE UNIVERSITY AND THE

FATE OF THE HUMANITIES (2008).

195.

Andrew Pollack, Stanford to Ban Drug Makers' Gifts to Doctors, Even Pens, N.Y.

TIMES, Sep. 12, 2006, at C2.

196. Gardiner Harris & Benedict Carey, Researchers Fail to Reveal Full Drug Pay,
N.Y. TIMES, June 8 2008, at Al.
197. See Stephen S. Hecht, Tobacco Carcinogens, Their Biomarkers and TobaccoInduced Cancer, 3 NATURE REVIEWS CANCER 733 (2003).
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not-and may not-facilitate the development of new drugs in the near
term. Does this mean genomic research is a failure? Perhaps not. As
genome resequencing becomes commonplace, the practice of medicine
without regard to the individual genetic makeup of patients may become
untenable because our genomes may be most informative about which
drugs not to take. 198 Although the details of how genomic research will
provide clinical utility remains unclear, there is no doubt that research is
continuing apace, which at the very least will provide vast amounts of
potentially useful biomedical data.

,Disease
...
treatment
Pharmaceutical model
Exclusive rights

Disease prevention..
...

Strong patents

-mos
-_
=Open source
mmonsapproac

A
Figure 1: A conceptual framework for competing models of medical
research. Large boxes represent the dominant biomedical research
models that have been supported by the pharmaceutical industry and
statutory efforts.
Smaller ovals represent potential alternative
approaches. The fulcrum is placed to the left to symbolize a potential
shift emphasized by genomic research and ethical imperatives including
the need to empower patient research participants.
A startling degree of genetic diversity has been uncovered in patient
samples analyzed using high throughput sequencing technology. 99
Translating the vast amount of genomic data being generated into health
benefits for society, e.g. by creating useful diagnostic tests, will require
significantly greater participation of patients and healthy volunteers in
tissue banking and genomic analysis trials. And yet, our current legal

198. See generally, Russell A. Wilke et al., Identifying Genetic Risk Factorsfor Serious
Adverse Drug Reactions: Current Progress and Challenges, 6 NATURE REVIEWS. DRUG
DISCOVERY 904 (2007).

199.

See, e.g., Xiang et al., supra note 42.
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framework disenfranchises patients who donate tissue for research by
denying ownership rights and by restricting the sharing of information. In
the future, successful development of clinically useful genomic tests may
require more positive incentive structures 200 to engage individuals needed to
contribute tissue and personal health information. Our medical practice
model, currently dominated by the pharmaceutical industry, may also have
to be reconsidered (see Figure 1). Finally, genomic research has revealed
unanticipated complexity and a "long tail" of genetic variants that may
demand data mining approaches unfettered by strong IP constraints
(perceived or actual). Creative commons approaches may facilitate broadbased searches for needed healthcare solutions. These approaches may put
personal and genomic data IP in the public domain while we search for
useful genomic tests (as with the Personal Genome Project). Alternatively,
IP ownership rights may be shared contractually with patients to encourage
their participation in, and to acknowledge their value to, continuing
genomic research.

200. The courts have ruled that patients do not share in ownership rights of intellectual
(or even physical) property arising from their donated tissues. See discussion infra Part
IV.C. Researchers looking for useful genomic tests may be motivated (presumably) by
several factors, including benevolence, potential notoriety, and potential monetary rewards.
Yet patients who contribute tissue necessary for this research can only be motivated by
benevolence under the current system. Providing greater incentives for patients to donate
tissue may be accomplished contractually, as opposed to a legislative change. Harvard
economist Roland Fryer's controversial experiments, whereby schools remunerate children
for good grades, provide a possibly relevant parallel to the subject matter at hand. See
Claudio Chavez, Pay-to-Behave Program Debuts in D.C. Schools, All Things Considered
(NPR radio broadcast Oct. 21, 2008), available at http://www.npr.org/templates/story/
story.php?storyld=95949912.
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